Total Knee Replacement Market Size, Share, Growth Analysis, By Type(Primary Knee Replacement Systems, Revision Knee Replacement Systems, Partial Knee Replacement Systems), By Implant Type(Fixed-Bearing Implants, Mobile-Bearing Implants), By Procedure(Total Knee Arthroplasty, Partial Knee Arthroplasty, Revision Arthroplasty), By Fixation Type(Cemented, Cementless, Hybrid, Reverse Hybrid), By End-Use(Hospitals, Orthopedic Clinics), By Region - Industry Forecast 2025-2032

The total knee replacement market is fragmented, with many large and small players in the industry. To gain market share, key players are implementing business strategies such as diverse product offerings, regional expansion, partnerships, and new product launches. For instance, De Puy Synthes' VELYS Robotic-Assisted Solution for use with the ATTUNE Total Knee System received 510(k) clearance from the US FDA in January 2021. Furthermore, in January 2021, Stryker acquired OrthoSensor, Inc, a pioneer in the digital evolution of total joint replacement. This acquisition has strengthened its market position.

Total Knee Replacement Market Top Player's Company Profiles

• Zimmer Biomet
• Stryker Corporation
• Smith & Nephew plc
• Johnson & Johnson Services Inc. (DePuy Synthes)
• MicroPort Scientific Corporation
• B. Braun Melsungen AG
• ConforMIS Inc.
• DJO Global Inc.
• Exactech Inc.
• Corin Group PLC
• Arthrex Inc.
• Colfax Corporation (DJO Global)
• Medacta International SA
• OMNI Life Science Inc.
• Ortho Development Corporation
• Smith & Nephew plc
• Waldemar Link GmbH & Co. KG
• Beijing Montagne Medical Device Co. Ltd.
• Limacorporate Spa
• JRI Orthopaedics Ltd.

Total Knee Replacement Market Recent Development

• In September 2022, Palm Beach Gardens Medical Center expands its orthopedic program with the acquisition of two Mako SmartRoboticsTM, the only and first in Palm Beach County. Dr. Robert Avino, an orthopedic surgeon, completed the first case at the hospital using Mako SmartRoboticsTM.
• In August 2022, Moximed, a medical device company on a mission to improve the standard of care for people suffering from knee osteoarthritis (OA), announced a $40 million Series C equity and debt financing round. Advent Life Sciences led the round, which also included returning investors New Enterprise Associates (NEA), Future Fund, Vertex Healthcare, Gilde Healthcare, GBS Venture Partners, and Morgenthaler Ventures, as well as debt financing from Runway Growth Capital.
• In August 2021, Zimmer Biomet Holdings, Inc. and Canary Medical announced a De Novo classification grant and permission to market the tibial extension for Persona IQ, the world's first and only FDA-cleared smart knee for total knee replacement surgery.